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Despite a well-established role for dopamine (DA) in the
neuropathology of schizophrenia, and the evidence of a
hyperdopaminergic state in the schizophrenic brain, many
questions still remain. Typical agents acting predominantly
on DA Dz receptors are only partially effective. lew data
now indicate that the interaction between DA and the various
DA receptors as well as DA interaction with other transmitter
systems, are more critical in deciding the therapeutic success
of an antipsychotic than actions on DA alone. These
interactions are closely associated with what is being
documented regarding the neuro-anatomy, neurobiology and
neuropsychology of the disorder.
There have been major advances in the understanding of
the neuropathology of schizophrenia that, while not replacing
the original DA hypothesis, have forced a re-evaluation of
our understanding of the disorder. In this paper we present
the biochemical and neuropathological basis for
schizophrenia and discuss six new atypical antipsychotics
according to these theories. Drugs reviewed include
clozapine, risperidone, olanzapine, ziprasidone, sertindole
and quetiapine.
While not a comparative analysis of these drugs, this
paper is an appraisal of how their pharmacology correlates
with our present knowledge of the disorder and highlights
differeI1ces among the drugs in thiS group. These agents
therefore possess specifically designed qualities, to varying
degrees, promising a significant improvement over earlier
agents in terms of treating positive and negative symptoms,
with a minimal risk of extrapyramidal symptoms (EPS).
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These qualities include an emphasis on Dz selectivity, D1/Dz
balance, DA/serotonin (5HT) balance, D3 /D, selectivity,
DA/ acetylcholine (Ach) balance and glutamate
(Glu)/garruna-aminobutyric acid (GABA) balance. The drugs
are discussed with reference to these criteria.
Targeted drug design has created a goal-directed strategy
with which to treat schizophrenia. These new antipsychotics
appear to have several distinct advantages over their
predecessors, and should make a major contribution to the
treatment of schizophrenia and the re-integration of these
patients into society.
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Schizophrenia is an extremely debilitating disorder that often
presents with a poor long-term prognosis. Despite the proven
efficacy of the neuroleptic agents currently a~ailable, outcome
statistics still reflect a disorder that is difficult to treat. These
statistical data emphasise the hidden costs associated with
schizophrenia, and suggest an urgent need for new and more
effective treatment strategies. Approximately 50% of
discharged patients will be rehospitalised within a year. Two-
thirds of first-episode patients continue to experience positive
symptoms after a year, and about one-third will continue to
have them after 6 years.' Less than 20% of schizophrenics are
employed at anyone time.' Patient scores on subjective and
objective measures of quality of life are very poor, and 10% of
patients with schizophrenia will commit suicide.' On the issue
of drug treatment, 20% of schizophrenic patients experience a
relapse despite antipsychotic medication,' while approximately
hvo-thirds of patients on medication for schizophrenia
experience persistent parkinsonism.
There is now strong evidence to support the suggestion that
the long-term outcome of first-episode schizophrenia can be
significantly influenced by the choice and dose of agent made
at the start of treatment.' Pharmacotherapy is often more
successful in. these patients, while studies also reveal that they
respond better at lower·doses. They are also more sensitive to
extrapyramidal symptoms (EPS). Recent data also suggest that
there is no advantage in using higher than nominal doses in
treatment-resistant cases' and that the equivalent of 100 - 700
mg/ day of chlorpromazine constitutes an adequate dose range
for most psychotic patients.' Consequently, since experiencing a
dystonic reaction may influence long-term compliance and
possibly be a risk factor for relapse,' use of an agent with low
EPS liability, or using a lower dose, will have significant impact
on the overall outcome. In addition, after each subsequent
relapse there is a drop off in response to treatment,' resulting in
the long-term morbidity figures quoted earlier. Therefore, a
good response from the outset predicts a better outcome, and
all these points can be significantly influenced by the choice of
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medication. Experience with clozapine indicates that such a
prudent choice can reduce hospitalisation and indirect costs
associated with the illness.' Despite their initial high cost,
therefore, the use of a new improved agent as first-line choice
may have significant cost-effective benefits in the long-term
management of schizophrenia.
Although the exact cause of schizophrenia is still unknown,
innovative and pioneering research into the pathogenesis of
schizophrenia is revealing new information about this
enigmatic disorder. As research probes this frontier, the
ensuing observations and ideas are becoming instrumental in
providing pharmaceutical chemists with neurobiological
targets around which potentially new and better agents are
being developed. The initial observations demonstrating the
antipsychotic action of D2 receptor antagonists, such as
chlorpromazine and haloperidol, were instrumental in shaping
our understanding of schizophrenia. Later, greater emphasis
on dopamine (DA) D, receptor selectivity led to the proposed
value of the D,-specific actions of sulpiride and other
substituted benzarnides. In more recent years, the realisation
of the critical role of serotonin (SHT) and its potential role in
the modulation of EPS induced by overt D, blockade has led to
the development of D,/ SHT2 receptor antagonists, including
ziprasidone, sertindole and risperidone. Finally, the well-
established clinical efficacy and favourable EPS profile of
clozapine, fuelled by observations that schizophrenia is
probably an imbalance in DA as well as disturbed SHT,
glutamate (Glu), acetylcholine (Ach), gamma-aminobutyric
acid (GABA) and neuropeptide function, has rekindled interest
in the role of the multireceptor antagonist. This has paved the
way for the development of clozapine-like agents such as
olanzapine and quetiapine.
While antipsychotics have in the past been classified in
various ways, e.g. chemical structure, therapeutic effects,
receptor affinities and as atypical/typical, it would appear
more logical to classify the new atypical agent according to the
specific concept of the neuropathology of schizophrenia that
has spawned its development. All the agents discussed in this
paper, but especially risperidone, ziprasidone and sertindole,
exploit the benefits of a high SHT2 /D2 receptor-blocking ratio,
proposed to be crucial in both an improved efficacy with
regard to negative symptoms and inducing a low incidence of
EPS. Olanzapine, quetiapine and clozapine, while also
displaying prominent SHT2 over D2 antagonism, also act at
various other receptor sites, which the aforementioned three
have less affinity for, and which may have additional benefitsI for the overall treatment of the disorder. These include
antimuscarinic actions, alpha-2 adrenoceptor antagonism, Glu
actions, DJ antagonism and D3 /D. antagonism. However,
affinities for alpha-1 and histamine H, receptors carry a side-
effect risk that may vary from one agent to the next. 0 doubt
as we learn more of the neurobiology of the illness, new
approaches to treating schizophrenia will become available.
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There are various candidate atypical agents in development.
Some, like zotepine, follow the same rationale as those
discussed in this paper.' However, there are a few agents that
are attempting to tread new ground. Two promising options
are the concept of the partial dopamine agonist, while another
is to focus on the glutamate hypothesis of schizophrenia. The
ideal partial agonist with suitable intrinsic activity should be as
efficient as the dopamine antagonists in attenuating psychotic
symptoms by preventing absolute or relative
hyperdopaminergia, but should be unable to induce
hypodopaminergia that would result in troublesome motor and
mental side-effects.' L-701,324 is a full antagonist at N-methyl-
D-aspartate (NMDA) receptor sites and pre-clinical data
suggest an atypical neuroleptic profile,6 while D-cycloserine, a
partial MDA-glycine site agonist, has similarly shown
promise as an atypical agent.'
Despite there being much debate on the definition of the
'atypical' antipsychotic and what properties confer 'atypicality',
this classification has nevertheless found favour due to its
conceptual appeal and seductive simplicity. However, these
very same attributes may be inappropriate and misleading for
various reasons.
Firstly, there is no generally accepted definition of the
concept'atypical'. The most widely used criterion is a low level
of EPS, but it is not unusual to include other criteria such as a
low level of tardive dyskinesia (ID), no prolactin release and a
beneficial effect on negative symptoms in patients who are
poor responders. Whether a particular agent exerts primarily a
direct anti-negative action or is secondary to its lower motor
side-effects, antidepressant action and/ or antipsychotic action,
remains an issue that is often difficult to interpret from clinical
trials. This has been overcome to some extent with the use of a
path analysis, although further work is still required.' This
analysis determines whether a significant difference still
remains after co-varying the negative symptom response with
the above three effects of the drug. Secondly, the atypical
antipsychotic group encompasses compounds that display a
wide variety of pnarmacological effects, ranging from pure D2
antagonists to multiple receptor antagonists. Finally, the
atypicality of an agent has entailed a strong focus on EPS to the
detriment of other side-effects, such as weight gain and sexual
disturbances. The new atypicals are characterised by these side-
effects to varying degrees.
This paper will attempt to determine the extent to which the
newer agents have improved the pharmacotherapy and
outcome of schizophrenia by examining their individual
pharmacological properties. The ultimate comparison will be
through controlled clinical trials. However by examining the
pharmacology of these agents and using a new paradigm
created by the latest thinking around the aetiology and
neuropathology of schizophrenia, some speculative ideas can
be put forward.
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Fig. 1. Schematic representation of serotonergic-dopamine
interactions in the striatum and prefrontal cortex.
Serotonergic tracts from the DRN inhibit dopaminergic function at
the DA cell body (A9 or substantia nigra) and at the end-synapses
located in the caudate nucleus of the striatum through 5HT2
heteroreceptors. Similarly, serotonergic tracts innervating the cortex
suppress DJ receptor function in the limbic prefrontal cortex VIa ..
5HT2 heteroreceptors. 5HT function is regulated by somatodendrzhc
5HTJa autoreceptors in the DRN. (Ach = acetylcholme; Glu =
glutamate; GABA = gamma-aminobutyric acid; DRN = dorsal
raphae nuclei; N Ace = nucleus accumbens; AID = ventral tegmental
nuclei; A9 = substantia nigra; PR = pars reticulata; PC = pars
compacta.)
pathway; the mesocorticolimbic (MCL) tract, has two
endpointsY The first projection, originating from the ventral
tegmental area (VTA) or A10 nuclei, innervates the limbic
structures such as the nucleus accurnbens, amygdylla, ventral
hippocampus and prefrontal cortex (mesolimbic pathway; Fig.
1), and supports a variety of behavioural functions related to
motivation and reward. This pathway is an important site of
antipsychotic action against positive-symptom psychosis. The
second A10 projection innervates the limbic cortex, e.g. the
medial prefrontal, cingulate and entorhinal areas, and is
involved in volition and affect (mesocortical pathway; Fig. 1). A
third major DA tract, the tubero-infundibular projection (TIP),
projects from the median eminence of the hypothalamus into
the anterior lobe of the pituitary where it subserves neuro-
endocrine functions, especially the control of prolactin
secretion.13 Consequently, non-selective block of both DJ-like
and D,-like families with a typical agent will not only induce a
desired antipsychotic action through their action on mesolimbic
D3 and D. receptors, but will also induce a high incidence of
EPS due to D2 block in the striatum. Furthermore, unopposed
D1 block in the mesocortical pathway is associated With
symptoms akin to negative-symptom schizophrenia known as
'neuroleptic-induced deficit syndrome'.13 EPS predisposes to a
more severe, possibly irreversible movement disorder, viz. ID.
ID occurs in 20% of all patients who are on extended
neuroleptic medication, and this can rise to 50% in the elderly. IS
Studies with clozapine have revealed that reducing the risk of
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NEUROCHEMISTRY OF SCHIZOPHRENIA-
RELATION TO THE NEW-GENERATION
ANTIPSYCHOTICS·
Role of DA and its relevance to schizophrenia
Some 50 years ago it was suggested that psychosis results from
an imbalance in brain chemistry, with observations that
hallucinogens such as lysergic acid diethylamide (LSD), and
later amphetamine, psilocybine and mescaline and the more
recent phencyclidine (PCP), could induce a schizophrenia-like
state. The introduction of agents such as reserpine, which
depletes central nionoamines, and Chlorpromazine, which
blocks DA receptors, indicated that psychoses could also be
treated by chemical means. A paradigm of hyperdopaminergic
function in the schizophrenic brain soon took shape. Using
neuroleptics radiolabelled with isotopes coupled with positron
emission tomography (PET), investigators were not only able to
demonstrate a high degree of binding to DA receptors by these
agents, but were also able to visualise and measure the extent
of binding, or occupancy, in the brain of human subjects. They
found a strong correlation between potency in binding these
receptors and response to the antipsychotic. However, while
therapeutic levels of the classic neuroleptics correlate with high
D2 receptor binding, therapeutic levels of clozapine correlate
strongly with binding to the D. receptor and less to the D2
receptor! Clearly, this pharmacological difference has clinical
implications, since it becomes apparent that unlike the classic
neuroleptics, clozapine was found to be effective in treating
negative-symptom schizophrenia and also has a much lesser
tendency to induce EPS. Clearly other mechanisms,
exemplified by clozapine, could be explored for a more specific
action against the symptoms of schizophrenia.
DA receptors are classed into two major families, viz. those
that stimulate cyclic adenosine monophosphate (cAMP)
synthesis as second messenger, namely the D1 and D5 receptors
(termed D1-like family), and those that either suppress or do
not affect cAMP, namely the D2< D3 and D. receptors (termed
D2-like family.)lo-U A discovery of great clinical value is that
these DA receptors have also been found to be anatomically
selective in their distribution and density in the brain. D1
receptors are prominent in the cortical regions, D2 receptors are
prominent in the striatum while the D3 and D. subtype of the
D2 family of receptors are expressed to a greater degree in the
limbic regions of the brainY Considering the source and
distribution of doparninergic pathways in the brain, there are
three major DA projections. The nigrostriatal ( S) pathway,
projecting from the st.!bstantia nigra, or A9 nuclei, of the
midbrain to the caudate and putamen in the neostriatum (Fig.
1), is involved primarily in extrapyramidal motor functions. 13 In
this context, it shares in a homeostatic regulatory role with
GABA and Ach, which act via interneurons to regulate the
behavioural actions of DA in the striatum.14 The second
A9 c::J 5 HT,. receplor
_ 5 HT, receplor
.. 0, receplor
c::J 0, receplor
Cortex
Striatum
Midbrain
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the more short-term EPS will lead to a similar reduction in
reported incidence of ID. Excessive O2 blockade in the TIP 1",ill
result in varying neuro-endocrine abnormalities such as breast
engorgement, gynaecomastia and other pituitary-mediated
hormonal fluctuations.
DA and other neurotransmitter interactions as
targets for antipsychotic action
D2-selectivity
With the notable exception of c1ozapine, most traditional
antipsychotic drugs block O2 receptors in direct correlation to
clinical potency." However, there appears to be some
differential sensitivity of the limbic and striatal O2 receptors
since high-potency (e.g. haloperidol) and low-potency (e.g.
chlorpromazine) antipsychotics are equally effective in their
respective dosage ranges, yet the latter are less prone to
causing EPS. A threshold for EPS has now been observed with
neuroleptics and can be used to predict with accuracy their
cataleptic potential.. yberg et al. 16 suggest that the threshold
for antipsychotic action is a O2 occupancy of 70%, with the O2
threshold for EPS being 80%, although EPS may start to appear
at striatal O2 receptor occupancy levels of above 70%.10.17 This
response is directly related to blood levels. The suggestion is
therefore that a dose-response curve for conventional
neuroleptics needs to be established. One aim, then, of the
'ideal' antipsychotic has been to target the MCL OA neurons
more selectively than those in the NS pathway in order to
achieve a better ratio between limbic (antipsychotic) action
versus NS (extrapyramidal) action. The archetypal group of
antipsychotics that explore this benefit are the substituted
benzarnides, of which sulpiride is the only representative
available in South Africa. Although the pharmacological profile
of sulpiride suggests an atypical action, it fails to satisfy any of
the prerequisites for atypicality, including low prolactin release
and low EPS (Table I). Furthermore, few studies can validate
the claims that sulpiride is effective for negative-symptom
schizophrenia,'· while those studies that have been performed
indicate minimal efficacy and only if negative symptoms are
not severe. Nevertheless, it would be valuable to discuss the
pharmacology of sulpiride and why it fails to satisfy the
criteria for an atypical antipsychotic. Like chlorpromazine,
sulpiride is a low~potency O2 antagonist that is superselective
for the O2 receptor, showing very little affinity for 0] and 0 5
receptorsI ' As with other benzarnides, it also appears to act
more specifically on the presynaptic O2 autoreceptor.20 Since
nigral autoreceptors are predominantly of the O2 type,'1
blocking of this auto-inhibitory receptor will increase OA
release in the striatum, thereby reducing EPS. A similar
facilitative action on prefrontal cortex OA function may occur,
thereby improving negative symptoms. However, owing to its
poor oral bio-availability (approximately 35%) and poor lipid
solubility,'· it requires extremely high doses for adequate
antipsychotic action (600 -1800 mg/day)I' This implies. that
there will be a high degree of binding to peripheral O2 "
receptors, especially in the TIP, resulting in a high incidence of
galactorrhoea and amenorrhoea." Furthermore, these high
doses will also impact on striatal O2 receptors significantly
enough to cause EPS (Table I)"· In support of this, O2 receptor
occupancy has been foUnd to be 78%"· Experience seems to
emphasise that the drug is more useful in milder psychoses
dominated by negative symptoms rather than more agitated
conditions where positive symptoms predominate." ew, and
possibly improved benzarnides, such as arnisulpride and
raclopride, are at various stages of development.
0]/02 balance
The neostriatum is rich in both O2 and 0] receptors, while the
cortex expresses 0 1 receptors in much higher levels than the O2
receptor.22 However, this apparently low level of D2 receptor
expression may still be important for antipsychotic actions,
since chronic exposure to antipsychotics not only increases the
level of O2 receptors in the cerebral cortex, but also produces
substantial downregulation of 0 1receptors.22 This effect is
possibly linked to sub-cellular receptor interaction between 0]
and O2 receptor second messengers.22 Deficits in cOgnitive
Table I. Limbic selectivity, D 2 occupancy and the dystonia-EPS potential of the new-generation antipsychotici
DystOnia-inducing Therapeutic
AlO:A9 O2 occupancy dose (man)I' dose" EPS
selectivity?'O,3l (%) (mg/d) (mg/d) potential
Sulpiride NA 78" 2000-8000 600 -1800 ++18
Risperidone Slight 63 - 89"'.36 5 - 20 4 -16 oto ++13
[I Clozapine Yes 16 - 6836 < 1500 100 - 800 0"Olanzapine Yes 43 - 8936 24 - 96 10 - 20 0"
Quetiapine Yes 44'" 1200-4800 300 - 900 0877
Ziprasidone Yes 761• A 80 -160 oto +2"
Sertindole Yes NA 100 - 400 16 - 30 0"
Haloperidol No 75 - 891• 5 - 20 5 -20 +++"
o= no difference v. placebo; + = mild; ++ = moderate; +++ =severe.
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abilities are associated with cortical pathology, particularly
frontal lobe lesions, and diminished 0] stimulation has been
found to result in diminished activity in prefrontal cortical
neurons. Furthermore, it has been suggested that an
abnormally low 01\ function in the prefrontal cortex of the
schizophrenic brain sets the scene for a reactive increase in A10
OA activity resulting in an increase in mesolimbic OA function,
thereby producing the ensuing positive symptoms of the
disorder.'" Hence a cortical site of action for the neuroleptics
may be as important as a mesolimbic action. Lidow and
colleagues," however, suggest that there is an optimal balance
between cortical 0 1 agonism/antaggnism as too much of either
is associated with diminished cognitive functioning.
Although 0 1 blockade alone appears to have limited
antipsychotic action,lO.22 when combined with a traditional O2
block possible improvements can be observed in therapeutic
efficacy, and a decrease in EPS may be anticipated. The
striatum, principal input structure of the basal ganglia, receives
Glu stimulation from the cortex and responds through
activation of a direct GABA-ergic and an indirect GABA-ergic
innervation of the output stages of the basal ganglia, viz. the
medial globus pallidus (Fig. 2).24 The direct activation of
descending GABA-ergic neurons innervates the medial globus
pallidus, as well as the pars reticulata of the substantia nigra
(Fig. 1), and is dependent on excitatory 0] receptor activation.
The activation of the descending indirect GABA pathway is
CORTEX
Fig. 2. Schematic representation ofdopamine-GABA-glutamate
interactions in thalamocortical-striatal circuits. (Refer to text for
further discussion.) (Glu = glutamate; DA = dopamine; SN =
substantia nigra; STN = subthalamic nucleus; IGP = lateral globus
pallidus; mGP = medial globus pallidus. Glu pathways = black
arrows; DA pathways = hatched arrows; GABA pathways = white
arrows.)
mediated by inhibitory O2 receptors on its cell body that
activate a two-stage GABA inhibitory segment, through the
lateral globus pallidus and then the subthalamic nuclei before
activating the medial globus pallidus through an excitatory Glu
pathway (Fig. 2)." Thus, OA exerts a differential action on these
two pathways that effectively determines the degree of
activation of the thalamic nuclei and its subsequent activation
of the cortex. It is known that dyskinesias associated with OA
agonists, such as L-dihydroxyphenylalanine (L-dopa) and
bromocriptine, are due to their ability to create a neurological
imbalance between these descending striatal 0 1- and O2-
mediated pathways innervating the thalamus. Consequently,
suppression of O]-mediated activity coupled with O2
stimulation, as in the case of bromocriptine, creates a relative
imbalance in these two pathways resulting in less effective
control over thalamic output, thereby inducing abnormal motor
activity." Contrary to bromocriptine, pergolide, a 0 1/02
agonist, appears to be less prone to inducing dyskinesias and is
more effective in reversing L-dopa-induced dyskinesia." The
reverse also applies, such that an imbalance in antagonistic
actions on striatal 0 1/02 activity may also lead to a greater
prevalence of dyskinesias and EPS. Agents such as flupenthixol
and zuclopenthixol, which combine approximately 80% O2
occupancy and 15 - 35% 0 1 occupancy, have demonstrated
some minor clinical advantage." However, where there is less
of a difference between 0 1 and O2 antagonism, as with
clozapine, olanzapine and ziprasidone, an improved EPS
potential may become evident.
D3 and D4 selectivity
Owing to the greater concentration of 0 3and O.j receptors in
the MCL tract," select antagonism of these receptors together
with less affinity for O2 receptors present predominantly in the
striatum, will allow for greater antipsychotic efficacy without
paying a high cost in terms of EPS. However, the exact role of
the 0 4 receptor has been questioned," and recent evidence,
using a novel selective O.j antagonist," has revealed no obvious
benefit in treating schizophrenia." The 03receptor has also
raised some interest," although its exact role is uncertain due to
there not being a select ligand available. It may prove to be the
basis for the atypical action of sulpiride, which has a high
affinity for this O 2 receptor subtype1 '." Select actions on limbic
O2 receptors, with minimal actions at striatal O2 receptors, have
distinct clinical value not only in the treatment of
schizophrenia, but also in the treatment of dopaminergic-
induced psychosis in Parkinson's disease, where striatal actions
would be highly undesirable. Clozapine, olanzapine and
risperidone have been found to be of value in these cases,
without exacerbating parkinsonism.'" Studies determining the
differential inhibition of limbic A10 versus S A9 neurons
indicate that mesolimbic A10 selectivity is achieved with
clozapine, quetiapine, olanzapine, ziprasidone and sertindole
and to a lesser degree with risperidone (Table 1).30.31
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5HT/DA balance
It is well documented that serotonergic agents, such as the
selective SHT re-uptake inhibitors, may induce or exacerbate
EPS, while SHT2 antagonists can alleviate or prevent it."
Serotonergic projections from the dorsal raphae nuclei project
to the substantia nigra where they act on somatodendritic 5HT2
heteroreceptors on dopaminergic neurons to inhibit theirfiring
(Fig. I)." Similarly, serotonergic projections from the dorsal
raphae project via the median forebrain bundle to the striatum
and cortex, to inhibit neuronal firing by decreasing synthesis
and/ or release of DA. As can be expected, lesioning these 5HT
pathways will cause a disinhibition of DA neurons and an
increase in DA levels." SHT1a agonists will effectively reduce
serotonergic outflow, thereby attenuating post-synaptic SHT2
receptor function in the SN and striatum." This action
effectively disinhibits DA function. The SHT2c receptor also
appears to play a role in the genesis of psychosis, since agonists
at this receptor can exacerbate the positive symptoms of
schizophrenia'2 Both SHT and DA tracts converge in the
ventrolateral nucleus accumbens, suggesting a dual role in
psychotic behaviour.33 LSD exerts its hallucinogenic effect
through stimulation of the SHT2 receptor.13 While the clinical
relevance of these effects is uncertain, SHT2c antagonism may
contribute to antipsychotic action.'"
Since Dj and D2 receptor blockade may be facilitated or
augmented in the forebrain and midbrain areas by 5HT,
antipsychotics with inherent 5HT2 receptor-blocking action or
SHTja presynaptic autoreceptor agonist activity will allow
disinhibition of the D2 receptors in the striatum, thereby
alleviating neuroleptic-induced EPS. Such a drug may have
further therapeutic advantages, although recent studies refute
this supposition.35.36 The negative symptoms of schizophrenia,
including anhedonia, apathy, blunted affect, and poverty of
speech, respond with great difficulty to typical antipsychotics,
and many patients freed from their delusions and
hallucinations are still unable to resume productive lives
because of enduring negative symptoms. Evidence is that these
symptoms reflect, in part, hypodoparninergic Dj receptor
function in the prefrontal cortex.22 Clozapine may act to
increase DA in the prefrontal cortex by stimulation of
presynaptic 5HTja autoreceptors.37 Furthermore, these effects on
SHTja and 5HT2 receptors may also constitute an
antidepressant-like action,13 which may contribute to their
efficacy against negative symptoms. Atypical agents have been
associated with induction of mania.38,39 Drugs with prominent
SHT2 receptor inhibition include most of the new atypicala agents, viz, clozapine, olanzapine, risperidone, ziprasidone,
quetiapine and sertindole. Recently, SHT receptors specific for
the striatum, viz, SHT(y and hypothalamus and limbic areas,
viz. SHT7, have been identified, and may have significance in
future drug development.'" A disadvantage of SHT2 block is its
association with weight gain, However, evidence suggests that
weight gain on psychotropics may be more pronounced with
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agents with combined 5HT2 and H j receptor antagonism than
with either of these agents alone.'" As such, clozapine,
olanzapine and quetiapine will induce this side-effect to a
greater degree.
DA!Ach balance
Designing an antipsychotic drug with a strong antimuscarinic
action may counter the cortical-striatal DA/Ach imbalance
induced by the powerful D2 block that underlies movement _'
abnormalities seen in Parkinson's disease and iatrogenic -;
parkinsonism (Fig. 1).14 This, however, would also confer a
higher incidence of typical anticholinergic side-effects that may
be troublesome to the patient. Furthermore, a theory of
cholinergic hyperactivity has been suggested as a basis !or
negative symptoms:' suggesting a possible benefit of
anticholinergic action in negative-symptom schizophrenij3..
Agents that may utilise these benefits would include clQiapine
and olanzapine; in addition preliminary evidence suggests that
both clozapine42 and olanzapine"have distinct benefits in terms
of improving cognition. The mechanisms of this response are
undefined at present, and in fact appear paradoxical. The
cognitive impairment typical of Alzheimer's disease (AD)
appears to be strongly associated with diminished cholinergic
functio~, thus raising the question of how an anticholinergic
property would benefit the cognitive impairment seen in
negative schizophrenia. The improvement in cognition
observed with the above two agents may occur secondary to
improved EPS, improvement in negative symptoms or through
another more complex mechanism. Furthermore, cholinergic
agonists produce only limited improvement in AD,13 thus
implicating additional pathways in memory and cognitive
function. Hippocampal Glu pathways are strongly implicated
in memory formation, with Glu hypofunction associated with
memory loss and diminished cognitive function. 13 Distinct
diminution in Glu function has been observed in the
hippocampus and cortex of schizophrenics (see following
section). A recent study indicates that administration of the
non-competitive antagonist of the NMDA subtype of Glu
receptor, PCp, results in DA dysfunction in the dorsolateral
prefrontal cortex and is accompanied by distinct cognitive
deficits.'" A role for Ach is possible in this context since Ach
exercises a permissive action in Glu-induced neuronal
excitotoxicity.'" The neurotoxic action of Glu, resulting in death
of Glu neurones, can be inhibited by anticholinergic agents,"
suggesting that an additional anticholinergic action may be
advantageous in addressing negative symptomology and in
preventing the longitudinal deterioration, including
refractoriness and relapse,'" so often observed in schizophrenic
patients.
GABA/Glu balance
The striatal complex, comprising the striatum and globus
pallidus, is under inhibitory control of thE: NS DA pathway,
and under stimulatory control of the glutamatergic pathway
.,
...-
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Fig. '3. Structural formula for the new-generation atypical
antipsychotics.
I Atypical' new-generation antipsychotics
While there are many experimental agents at various stages of
clinical development, we will be focusing specifically on those
atypical agents already available in South Africa, or that may
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the agents discussed in this review have not been fully
explored, although it is anticipated that some of the newer
drugs, such as D-cycloserine, will exploit this mechanism. A
recent study" suggesting a role for agonists at the presynaptic
auto-inhibitory metabotropic subtype of the Glu receptor may
also represent a novel non-DA approach to the treatment of
schizophrenia. The multi-receptor antagonists clozapine,
quetiapine and olanzapine have been shown to antagonise the
behavioural effects of Glu- TMDA receptor antagonists such as
phencyclidine and MK-801.41.5O While these data support the
Glu hypofunction hypothesis of schizophrenia, Swerdlow
et al.'" found that haloperidol and risperidone were devoid of
this ability, such that the full implication in the treatment of the
disorder remains specuiative at present.
H
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from the cortex and thalamus (Figs 1 and 2)." This balance of
power maintains an inhibitory GABA-ergic action on the
thalamus leading to a reduced transmission of sensory
information to the cerebral cortex. However, any condition
causing a loss of or diminished Glu tone would be equivalent
to an elevated DA tone, namely insufficient suppression of the
thalamic output to the cortex causing hyperarousal, confusion
and psychosis." There is significant evidence implicating Glu
hypofunction in the chemical pathology of schizophrenia. PCP
and ketarnine, two dissociative anaesthetics, are
psychotomimetic by virtue of their ability to block the NMDA
receptor." Furthermore, the princip'!J. second messengers
induced by NMDA activation, viz. Ca2., nitric oxide and cyclic
GMP, are also modified by antipsychotic medication.'"
Prolonged NMDA hypofunction also results in limbic and
neocortical neuronal damage not urilike that seen in the
schizophrenic brain." Hypofunctional Glu receptors ultimately
impact on GABA transmission, resulting in impaired GABA
control over corticolimbic neurons. An initial excitotoxic insult
early in development may destroy either the NMDA receptors,
or the GABA neurons expressing these receptors, resulting in
an unopposed disinhibition of unrnodulated stimulatory
activity that floods corticolimbic brain regions. Such a lesion is
asymptomatic in the developing fetal brain. However, these
damaged circuits may be recruited in early adolescence, with
the ensuing presentation of psychotic symptoms, and may later
lead to ongoing structural damage. Studies done on rat pups
have demonstrated an age-related sensitivity to NMDA
antagonists, where the animals are resistant to the neurotoxic
effects of MK-801, but become sensitive after puberty." In man,
an analogous result using ketarnine has demonstrated the
relative lack of psychotogenic effects of ketarnine in pre-
adolescent children, with these effects becoming prominent in
adolescents and adults."
Further supportive evidence for in utero excitotoxic cell death
comes from the consistent neuropathological finding that
gliosis is absent in the schizophrenic brain, in spite of the
apparent neurodegenerative profile of the disorder (viz. cortical
volume loss, enlarged ventricles). Gliosis is an associated
finding in most neurodegenerative diseases, e.g. Alzheimer's
disease and Parkinson's disease, but is not found in
neurodegenerative disorders that occur early in brain
development." In addition, cyto-architecture studies done on
the schizophrenic brain indicate that there is a laminar
distribution of cortical neurons inwards. This implies that the
neurons destined for the cerebral cortex, which normally
proceed outwards from the periventricular sheath of the neural
tube, have died off and therefore not reached their intended .
destination." Neuropsychological studies also support an early-
onset brain abnormality. Children who will later develop
schizophrenia have been found to have distinct neuromotor
and neuropsychological deficits in early childhood before any
psychiatric symptoms appear." The actions on Glu function by
be introduced in the near future. These include clozapine,
risperidone and olanzapine (already available), sertindole and
quetiapine (available elsewhere, e.g. the USA and Europe), and
ziprasidone, which is in late-stage development. Their chemical
structures are depicted in Fig. 3.
Serotonin-dopamine antagonists
Risperidone (Risperdal; Janssen-Cilag)
This agent was developed following observations that the
selective 5HT, antagonist, ritanserin, improved negative
symptoms and reduced EPS when combined with
haloperidol.51 Risperidone is a high-potency antipsychotic
belonging to the benzisoxazol family. It offers greater 5HT'a
antagonism relative to D, receptors," a profile which, as
predicted by the 5HT/DA balance theory discussed above,
should afford it a low risk of EPS. At doses at the lower end of
its dosage range « 6 mg/ day), few EPS are experienced and its
efficacy against negative symptoms and occurrence of EPS is
markedly superior to that of 20 mg/ d haloperidol. Single-dose
PET studies using subclinical dosages of 1 mg reveal 50%
occupancy of both 5HT, and D, receptors." Since this response
is dose-dependent, it can be predicted that higher occupancy
will occur at its clinically relevant doses. Recent PET studies
have therefore revealed a high degree of D, occupancy in the
striatum at a 6 mg / day dosage, viz. 75 - 80%53 and over a 2 - 12
mg/ day dose range, viz. 63 - 89%.36 Since risperidone has no
inherent antimuscarinic activity, its low EPS profile is most
likely linked to its potent 5HT, antagonistic property," allowing
for DA disinhibition in the striatum and prefrontal cortex.
However, its cataleptic and therapeutic dosages are in the same
range (Table I) such that this mechanism alone appears not to
be enough to prevent EPS. Dosages higher than 10 mg/ day are
associated with an increasing incidence of EPS,I9 while
neuroleptic malignant syndrome (NMS) has also been
associated with its use." Nevertheless, risperidone, in
recommended dosages, viz. 2 - 6 mg/ day, is highly effective
against both positive- and negative- symptom schizophrenia,
causing fewer EPS than the conventional neuroleptics.'
Daily dosages in excess of 10 mg do not appear to offer any
added therapeutic benefit.51 In fact, in the higher-dosage groups
(12 - 16 mg), the therapeutic effect is lower than that produced
by 4 - 8 mg, suggesting that a bell-shaped response emerges for
the therapeutic effect as a function of dose.'" There is evidence
for a faster onset of action compared with typical agents," and
it appears more effective than these latter agents in managing
refractory schizophrenia.'" In addition, risperidone is finding
mI favour in the treatment of other conditions, such as psychosis
in the elderly' and mania.57 Continuation studies have revealed
that the drug maintains its response beyond the 8-week
double-blind period,' and that it is well tolerated and effective
in long-term tTeatment.51,56 A study comparing it with clozapine
in acute schizophrenia revealed no significant difference,'I
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while studies in refractory patients similarly reveal equal
efficacy."'" Risperidone presents with a significant degree of
alpha-1 adrenoceptor block, resulting in sedation, orthostatic
hypotension and cardiac palpitations. For these reasons,
titration of risperidone dosage is recommended." Due to
powerful5HT, antagonism, weight gain can be anticipated,"
while a marked increase in prolactin is also seen. I9 Although
the clinical relevance is uncertain at this time, risperidone also
has a high affinity for the 5HT7 receptor.59
Ziprasidone (Zeldox; Pfizer)
Ziprasidone is a medium-potency benzisothiazoyl piperazine
still in late-phase clinical trials. It has a purported dosage
range of 80 - 160 mg per day. The receptor binding of
ziprasidone is similar to risperidone, yet it is also unique,
binding significantly to D,-farnily receptors such as D3 apd D4-
but not D1receptors.'''' Ziprasidone binds to a great many 5HT
receptor subtypes, including 5HT"" 5HT,u 5HT1a and 5HT1d."
Affinity for the 5HT1a receptor may be associated with
anxiolytic effects.'" Since 5HT2c antagonism may contribute to
antipsychotic effects, this property may contribute to its clinical
efficacy." It has a moderate affinity for the alpha-1
adrenoceptor and the HI receptor, while its affinity for alpha-2
receptors and muscarinic receptors is negligible."" Ziprasidone
presents with a limbic-selective action" and it displays the
highest 5HT2 /D2 ratio among the new agents, being twice that
observed with clozapine." Early clinical trials indicate
comparable efficacy with haloperidol at dosages of 120
mg/ day.219 However, single-dose PET studies with a subclinical
dose of 40 mg and 60 mg demonstrate striatal D2 receptor
occupancies of 77% and 82%, respectively,"'" accompanied by a
robust elevation in prolactin release19." These observations
predict a relative risk for EPS that may be dose-related. As with
risperidone, its potent 5HT, antagonism will work to its·
advantage, provided dosages are not excessive. The clinical
profile,' therefore, reveals an agent that has both positive and
negative symptom efficacy, with a favourable motor side-effect
profile,' with little to no parkinsonism and akathisia noted.
Side-effects are also relatively predictable given its receptor-
binding profile, and include prolactin release, sedation,
headache, agitation and orthostatic hypotension. I9 No cardiac,
haematological and hepatic changes have been noted, while,
possibly because of a low Hl- binding, weight gain appears to
be less of a problem with this agent.'
Sertindole (Serlect/Serdolect; Lundbeck)
Sertindole, a phenylindole derivative, is a high-potency
product with a dosage range of 8 - 24 mg/ day. It, too, may be
tentatively grouped as a '5HT2 /D,/alpha-1 antagonist', along
with ziprasidone and risperidone. However, it diHers slightly
in that its D2 affinity is markedly higher than that of its
comparators" This would have impacted heavily on EPS had it
not also demonstrated the highest 5HT2 antagonism in the
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group." D2 receptor occupancy studies reveal significantly
lower striatal D2 binding compared with haloperidol, but
significantly higher binding than dozapine.'" evertheless,
sertindole has an estimated dystonia-inducing dosage in man
of 100 - 400 mg/ day, much higher than its therapeutic dosage
range (Table I),I' such that EPS is expected to be very low.
Furthermore, it inhibits VTA DA activity at doses lOO-fold less
than those needed to inhibit SN DA activity. Clinical trial data
indicate that sertindole produces motor side-effects
indistinguishable from placebo, both for parkinsonism and
akathisia.· The drug lacks affinity for the D, receptor family,
while its limited action on H, and Il].uscarinic receptors·
suggests a low incidence of sedation, dry mouth, etc. Due to
its powerful alpha-1 block, side-effects include headache, nasal
congestion and diminished ejaculatory volume, while insomnia
is also reported. Prolongation of the QT intervalI5'''''may occur,
although these ECG changes have not been related to clinical
signs or symptoms, e.g. syncope, arrhythrnias."" There appears
to be a low risk of seizures with sertindole,t5 as well as no
evidence for significant liver dysfunction or agranulocytosis."
A recent clinical trial comparing sertindole with haloperidol
revealed comparable efficacy in treating psychosis. Dosages at
the upper end of its range (20 mg/day) were found to be
superior to placebo in addressing negative symptoms." Its
apparent superiority in this regard over haloperidol became
noticeable after week 8 when the haloperidol response on
negative symptoms appeared to plateau." A path analysis
revealed a significant effect of the drug on negative symptoms.·
At all doses, haloperidol produced significantly more EPS, with
EPS for sertindole being indistinguishable from placebo.
Sertindole-treated patients remained free of hospitalisation and
medically compliant for significantly longer periods of time
than those on haloperidol.66 There is also preliminary evidence
to suggest efficacy in treatment of refractory psychosis.67
Sertindole may be comparable to clozapine in terms of
managing partially responsive schizophrenics.'"
Multireceptor antagonists
Oozapine (Leponex; Novartis)
Oozapine, a dibenzodiazepine, is the archetypal atypical
antipsychotic, and is the agent for which the most is known. It
is referred to as a multireceptor antagonist, having significant
affinity for D" D~ 5HT~ alpha-I, muscarinic and histamine-H,
receptors. It has a high affinity for the alpha-2 receptor, which
suggests a tentative role for this receptor in the atypical nature
of dozapine." The exact explanation for its atypical nature is
still the subject of speculation, although it may include a
number of the latest theories discussed earlier.
Significant efficacy on negative symptoms has been ascribed
to its antimuscarinic actions, alpha-2 antagonism, high
5HT2 /D2 ratio allowing D, receptor disinhibition and/ or its
mesolimbic-specific action via D4 receptor antagonism.
Clozapine presents with a high 5HT2 /D2 ratio" and a well-
established reputation for inducing few to no EPS. In addition,
its high antimuscarinic action, favourable D,/D2 antagonism
ratio and an extremely low occupancy of striatal D2 receptors,
viz. 16 - 68% over a dose range of 75 - 900 mg/ daY" may
contribute to this clinical profile. Clozapine has an estimated
dystonia-inducing dosage in man of 1 500 mg/ day compared
with its therapeutic range of 200 - 600 mg/ day. It has,
therefore, a markedly lower risk of causing acute and chronic
EPS, such as akathisia and m. It also has a unique binding
profile to the 5HT6 and 5HT7 receptors present in the striatum
and the limbic and hypothalamic areas, respectively, allowing
more specific targeting of 5HT effects on DA actions in these
areas.30.59 Affinity for the 5HT2c receptor may confer benefit for
positive symptom management." Numerous studies have
proved that dozapine has an antipsychotic effect equal to or
better than that of the typical antipsychotics, with significantly
better efficacy in treating positive and negative symptoms."
Superior benefits have also been noted with regard to its ability
to address cognitive impairment" as well as the general
psychopathology of schizophrenia, viz. anxiety, depression and
hostility. It is also superior in its ability to increase social
functioning, work capabilities and quality of life" and it can
reduce the risk of suicide.I' Outcome studies have clearly
indicated its ability to reduce hospitalisation, with 17% of
dozapine patients versus 32% on conventional antipsychotics
requiring hospitalisation after 1 year.' Clozapine has been used
with success in schizo-affective and bipolar disorders, while it
also has value in treating severe TO or tardive dystonia."
However, despite these unquestionable benefits, clozapine has
a 1% risk of causing potentially fatal agranulocytosis/ll possibly
associated with greater age and female gender." There may be
a genetic link as well as an immune component to this adverse
event." It is therefore normally restricted to treatment-resistant
patients who have failed to respond to two or more traditional
antipsychotics, where it has a success rate of 30 - 50%, and for
patients with unmanageable EPS and TO. Because of its low
potency (dosage range of 200 - 600 mg/ day), the high doses
required for its therapeutic effect will allow a high degree of
binding to other receptoi-s, resulting in a variety of autonomic
side-effects, e.g. sedation and postural hypotension." Due to its
high affinity for the HI receptor, and coupled with its potent
5HT2 antagonism, problems with weight can be a major
complicating factor as far as compliance is concerned. A
unique property of clozapine is its selective agonist activity on
the muscarinic M4 receptor/' as well as alpha-2 antagonism,"
which may be responsible for the high incidence of
troublesome hypersalivation that this agent causes.62.7Il
Clozapine also has a high risk of inducing seizures in
susceptible individuals, although there is a lower risk than
with the older typical agents. It is clearly dose-related, with the
incidence rising from 1% (300 mg/d) to 2.7% at 300 - 600 mg/d
and 4.4% for dosages in excess of 600 mg/ d." Despite nearly 25
••
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years of clinical use, there is still uncertainty regarding the
dosage range of this compound.' Dose titration, however, is
critical at the start of treatment.'1
Olanzapine (Zyprexa; Eli Lilly)
Olanzapine is a high-potency analogue of clozapine, with a
similar chemical structure (Fig. 3), and a similar pharmacology.
Chemically it is termed a thienobenzodiazepine. Olanzapine is,
therefore, a multireceptor antagonist with considerable affinity
for Dv D2I 5HT2I histamine H), alpha-l and muscarinic M)
receptors.70 Despite its potential to influe~ce many receptors, its
high.potency allows it a more select action on the required DA
and 5HT receptors without bringing about a heavy side-effect
burden.'" While anticholinergic side-effects are evident, they are
usually low « 15%).70 It presents with the highest
antimuscarinic action of the group:' an effect that may be
valuable in preventing the longitudinal cognitive deterioration
observed in schizophrenic patients!'-'" Its low but Significant
action on glutamate receptors""'" may also have a role to play in
improving long-term outcome. Olanzapine also binds strongly
to the newly identified 5HT6 receptor that has a high density in
the striatum, a profile that may well have a significant role to
play in allowing DA disinhibition in the striatum.'" Olanzapine,
similarly, has a high affinity for the limbic D4 receptor, while
PET studies indicate a single 10 mg dose D, occupancy in the
striatum to be 59 - 63%/' although a dose ranging study (5 - 60
mg) revealed 43 - 89% D, occupancy.36 Consequently, as evinced
from studies evaluatillg its dystonia potential in man, viz. 24 -
96 mg/ day, versus its nominal dosage range of 10 - 20 mg/ day
(Table I), it will have a low tendency to induce EPS within its
recommended dosage range. I ' Dual D)/D, antagonism may
also contribute here. This prediction of low motor side-effects
has been borne out in clinical trials,'" although akathisia73 as
well as NMS" have been noted. Unlike clozapine, olanzapine
has little to no affinity for the alpha-2 and 5HT7 receptor.70
Furthermore, it may induce a transient but clinically irrelevant
elevation of prolactin." Significant 5HT,/H)-blocking activity
predicts that weight gain will be a detrimental factor in
therapy. Treatment with olanzapine may be associated with a
transient elevation in the levels of hepatic transaminases, viz.
alanine aminotransferase, aspartate aminotransferase and
gamma-glutamyl transferase. However, no clinical symptoms
of hepatotoxicity were noted.70 Bearing in mind its close
structural similarity to clozapine, the most crucial question
relates to the relative risk of developing agranulocytosis. So far
there have been no reports of granulocytopenia, includingiiI reports of 32 patients who had previously experienced
clozapine-induced agranulocytosis and/ or neutropenia and
who switched to olanzapine.'" Olanzapine appears to have a
relatively low risk of inducing seizures.15 Placebo- and
haloperidol-controlled studies have revealed the efficacy of
olanzapine with regard to both positive and negative
symptoms of schizophrenia, with greater improvements in
negative symptoms compared with haloperidol.'" In addition,
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the agent also appears to have a relatively rapid onset of action,
with a response greater than placebo evident within 1 - 2
weeks."'''' A path analysis of the clinical trial data reveals that
olanzapine exerts a direct influence on primary as well as
secondary negative features.7• As a result, overall quality of life
is improved and there is a significantly higher probability of
maintaining a response over long-term treatment compared
with haloperidol. I.'" Olanzapine demonstrates efficacy in
schizophreniform disorders and schizo-affective disorder" a.§
well as bipolar disorder.'" Interesting results from a recent' '.
double-blind comparison between olanzapine and risperidone
in the same group of patients" provide evidence that
olanzapine is superior in negative symptom efficacy and
tolerability as well as in its ability to maintain a clinical.
response over time. However, this trial did not use doses of
comparable D2 occupancy36 and therefore comparisons s~ould
be interpreted with caution. Although preliminary case ieports
reveal efficacy at dosages exceeding 20 mg / day,so efficacy in
resistant schizophrenia still needs to be assessed definitively. A
double-blind study comparing olanzapine (22 mg ± 3.4
mg/ day) to clozapine (354 ± 146 mg/ day) provides evidence
that olanzapine is at least as effective as clozapine in treating
resistant schizophrenia."1 This latter study, however, requires
confirmation.
Quetiapine (5erequel; Zeneca)
Quetiapine, a dibenzothiazepine, is structurally similar to
clozapine and olanzapine (Fig. 3) and also acts as a multi-
receptor antagonist. However, it appears to have greater alpha-l
blocking action, with less potent D2 and 5HT2 antagonism,
slight D) blocking activity and minimal activity at muscarinic-
cholinergic receptors.' Quetiapine also demenstrates moderate
5HT and noradrenaline re-uptake blocking properties." It is a
low-potency agent (300 - 900 mg/ day), with an estimated
dystonia-inducing dosage in man of between 1 200 and 4 800
mg/day." It demonstrates dose selectivity for the AI0 DA
neurons in chronic treatment." A dose of 450 mg results in 44%
striatal O2 occupancy," suggestive of a low EPS potential, as
well as a low tendency to induce prolactin secretion. This has
been validated in clinical trials,83'" where little to no EPS or
elevated prolactin release was· noted.55 The drug also shows
promise in the treatment of DA agonist-induced psychosis in
patients with Parkinson's diseases, without exacerbating
parkinsonism." Quetiapine produces decrements in both
positive and negative symptoms in schizophrenia, and appears
to have similar efficacy to traditional antispychotics,1l.l although
efficacy in treating negative symptoms appears to be less
consistent.'-".83 As can be predicted from its multi-potent
receptor profile, common side-effects include sedation,
insomnia, postural hypotension, agitation and dry mouth,I' as
well as weight gain.83 Transient elevation in liver enzymes, a
reduction in thyroxine T4levels83 and transient neutropenia
have been noted.' Considering the decreased To/ there is no
evidence for an increase in thyroid-stimulating hormone or of
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clinical hypothyroidism.83 No effects on haematological and
electrocardiographic parameters and prolactin have bee~
noted.83
CONCLUSION
This paper reviewed the most recent pharmacological agents
for schizophrenia and discussed their characteristics in the light
of new work on the neurobiology of schizophrenia. Although
there are a number of theories that may be applied to the
development of the atypical antipsychotic, the theory most
exploited in these new drugs, and therefore of greatest value in
explaining their atypical action, is their superior 5HT2
antagonism over D2 antagonism. One might speculate that DA
antagonism accounts for the proximal antipsychotic effects,
while 5HT antagonism may be more beneficial for ancillary
symptoms and more distal outcomes, such as improved
functional status and quality of life. The addition of D3 or D.
antagonism, muscarinic antagonism, alpha-2 antagonism,
balanced D, /D2 antagonism and effects on Glu, as seen with
the multireceptor antagonists, may allow the mustering of a
greater clinical response with a lower Dz occupancy, thereby
allowing equal efficacy at lower doses and therefore less risk of
EPS.36 Certainly, agents with anyone of these properties alone
do not appear to be effective antipsychotics. Whether 5HT2/D2
balanced antagonism can be excluded in the light of newer
strategies, such as Glu antagonism or partial D2 antagonism,
will no doubt be evaluated in time.
The true value of these new atypical antipsychotics, their
ability to address adequately all the symptoms of
schizophrenia, namely to reduce long-term cognitive
impairment, to reduce hospitalisation and to allow maximal
reintegration of these patients into society, will only be borne
out over time. All the agents have demonstrated efficacy in
treating positive symptoms comparable with conventional
antipsychotics, while also demonstrating marked improvement
in EPS profiles. There is also evidence for efficacy in addressing
negative symptoms. However, their efficacy in this regard
compared with the atypical reference drug, clozapine, needs to
be assessed urgently. Exploration studies with these agents in
pre-adolescent children are also needed.87
Since it became available in the 1970s, the benefit of
clozapine has been without question. The pharmacological
aspects of this multi-potent drug, and the characteristics of the
ideal antipsychotic, still remain locked in our lack of
understanding of an extremely complex disorder. evertheless,
the new antipsychotics appear to have several distinct
advantages over earlier agents. Their more favourable side-
effect profile is likely to improve patient compliance. This,
together with improved efficacy across a broader range of
symptoms, should result in a better outcome, and an improved
quality of life for patients suffering from schizophrenia.
The authors acknowledge the Medical Research Council and
Potchefstroom University for Christian Higher Education for
financial support.
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